What changed
Deals & ownershipDuring the week of November 4, 2026, to November 10, 2026, executives and former managers at Labcorp Holdings Inc. filed notices regarding company stock transactions, including actual sales and proposed sales.

What changedLabcorp Holdings Inc. filed its 10-Q report for the third quarter of 2026, reporting quarterly revenue of $3,810 million, a 6.9% increase from the previous year. The document detailed several operational risks, including those related to implementing an enterprise resource planning (ERP) system, labor relations, and animal research activities.

What changedLabcorp Holdings Inc. reported financial results for the third quarter ended September 30, 2026. The company invested $255.5 million in acquisitions and paid $58.2 million in dividends.

Dividends & buybacksOn October 21, 2026, Labcorp Holdings Inc. declared a quarterly cash dividend of $0.72 per share. The payment is scheduled for December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

What changedLabcorp Holdings Inc. said CMS payment rates based on inaccurate data could lead to sharp annual cuts that threaten patient access to laboratory services, reaffirmed support for the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and said it continues to evaluate the impact of these rates on its 2027 financial guidance.

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
LABCORP HOLDINGS INC.: 12 recorded developments from 4 official sources in 2026-10.
- 2026-10-21: Labcorp Holdings Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. Source
- 2026-10-21: Labcorp employs nearly 71,000 people and serves clients in approximately 100 countries. Source
- 2026-10-21: Labcorp provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide. Source
- 2026-10-21: On October 21, 2026, Labcorp Holdings Inc. announced that its Board of Directors declared a cash dividend of $0.72 per share of common stock, payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026. Source
- 2026-10-28: The company supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025. Source
- 2026-10-28: The company performed more than 750 million tests for patients around the world. Source
- 2026-10-28: The company utilizes non-GAAP "adjusted" financial measures, which it believes are useful to investors as a supplement to GAAP measures. Source
- 2026-10-28: Transition services fees charged to Fortrea Holdings Inc. relate to administrative and IT systems support. Source
- 2026-10-28: The company announced its results for the quarter ended September 30, 2026. Source
- 2026-10-28: The company received FDA approval for PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma. Source
- 2026-10-28: In the third quarter of 2026, the company invested $255.5 million in acquisitions and paid out $58.2 million in dividends. Source
- 2026-10-28: The company signed agreements to acquire select assets of BioReference Health's laboratory testing businesses, the Prenatal Health testing business of Myriad Genetics, and Millennium Health. Source
September 2026
LABCORP HOLDINGS INC.: 6 recorded developments from 2 official sources in 2026-09.
- 2026-09-22: The Company believes the payment rates are based on data that is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services. Source
- 2026-09-22: The Company continues to support the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, a bipartisan solution that would ensure the U.S. has a sustainable and innovative laboratory system. Source
- 2026-09-22: The Company is continuing to evaluate the CMS payment rates and expects to provide additional information regarding the impact of the CMS payment rates on its 2027 financial guidance when that guidance is announced in February 2027. Source
- 2026-09-30: Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. Source
- 2026-09-30: We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Source
- 2026-09-30: The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference.
Said November 4, 2026 · Period named: November 10, 2026 · Source · Our article
Not yet checked against later reports.
The 2026 Biopharma Laboratory Services guidance includes a 1.3% impact from foreign currency translation.
Said October 28, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
The 2026 Enterprise guidance includes a 0.3% impact from foreign currency translation.
Said October 28, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| August 14, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 16, 2026 | Amy B. Summy | Sale notice filed | 365 | $372.58 | $135,992 | SEC |
| November 10, 2026 | Brian J Caveney | Sale notice filed | 2,000 | $372.04 | $744,080 | SEC |
| November 4, 2026 | Bailey Megan D. | Planned sale | 3,035 | — | $1,096,121 | SEC |
| November 3, 2026 | Bryan T Vaughn | Sale 10b5-1 plan notice filed | 306 | $353.70 | $108,232 | SEC |
| October 30, 2026 | Richelle P Parham | Sale notice filed | 1,078 | $361.22 | $389,395 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 6,535,506 | $2,013,654,791 | -0.6% | Q3 2026 |
| State Street | 3,943,551 | $1,215,047,499 | +0.9% | Q3 2026 |
| Fidelity (FMR) | 3,689,552 | $1,136,787,772 | +93.7% | Q3 2026 |
| Geode Capital Management | 2,186,220 | $670,899,215 | -0.1% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 810,093 | $226,826,040 | — | Q2 2026 |
| Wellington Management | 653,630 | $201,389,939 | -23.6% | Q3 2026 |
| Citadel Advisors | 265,420 | $81,778,556 | +650.5% | Q3 2026 |
| D. E. Shaw & Co. | 242,093 | $74,591,274 | +504.8% | Q3 2026 |
| Millennium Management | 59,429 | $18,310,669 | -73.9% | Q3 2026 |
| Two Sigma Investments | 7,249 | $2,233,489 | +168.5% | Q3 2026 |
| Bridgewater Associates | 2,654 | $817,724 | -5.1% | Q3 2026 |
| T. Rowe Price | 148,479 | $45,749 | +23.9% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.